Successful treatment of Favre-Racouchot disease with 0.05% tazarotene gel.
Rallis
Efstathios
E
Karanikola
Evmorfia
E
Verros
Constantinos
C
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005148:Facial Dermatoses / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D012176:Retinoids
D003879:Dermatologic Agents; D005782:Gels; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids